Skip to main content
Erschienen in: Journal of Neurology 5/2015

01.05.2015 | Original Communication

The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset

verfasst von: Helen Tedeholm, Bengt Skoog, Vera Lisovskaja, Björn Runmarker, Olle Nerman, Oluf Andersen

Erschienen in: Journal of Neurology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Interest in the long-term natural history of multiple sclerosis (MS) is being revived, as disability endpoints become increasingly important with the advent of highly efficacious long range but potentially harmful drugs. MS had an increasingly benign course, probably due to better assessment and changing diagnostic criteria. Incidence cohorts reduce inclusion bias, capturing both extreme benign and severe cases. We conducted a 50-year follow-up of an incidence cohort of Gothenburg residents with MS onset in 1950–1964 (n = 254; 212 with an initial relapsing-remitting course and 42 with a monophasic course, diagnostic criteria according to Poser). Patients were followed longitudinally until censoring, death, or study termination in 2012 and evaluated using Kaplan–Meier estimates and Cox regression analysis. Median time to secondary progression was 15 years. Median time to EDSS6 and EDSS7 was 26 and 48 years (n = 254), respectively. The cumulative risk of reaching EDSS6 was 50 % at 55 years of age and 80 % at 80 years of age (n = 212). A score based on a cluster of clinical features at onset predicted secondary progression, EDSS6, EDSS7, and EDSS10 (hazard ratio 1.6–2.3 per score unit for women, 0.99–1.49 for men). This score predicted the disease course during five decades indirectly, by predicting time to secondary progression. Age at onset predicted the course in men, with 3–6 % yearly increase in the risk of reaching disability milestones. The present incidence cohort provided hard outcome data in untreated patients over several decades.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH (2008) Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 30:234–238CrossRefPubMed Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH (2008) Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 30:234–238CrossRefPubMed
2.
Zurück zum Zitat Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21:S831–S838CrossRefPubMed Amato MP, Ponziani G (2000) A prospective study on the prognosis of multiple sclerosis. Neurol Sci 21:S831–S838CrossRefPubMed
3.
Zurück zum Zitat Andersen O (2012) From the Gothenburg cohort to the Swedish multiple sclerosis registry. Acta Neurol Scand Suppl:13-19 Andersen O (2012) From the Gothenburg cohort to the Swedish multiple sclerosis registry. Acta Neurol Scand Suppl:13-19
4.
Zurück zum Zitat Andersen O (2008) Natural history of multiple sclerosis. In: Raine C, McFarland HF, Hohlfeld R (eds) Multiple Sclerosis: a comprehensive text. Saunders Elsevier, Edinburgh, pp 100–120 Andersen O (2008) Natural history of multiple sclerosis. In: Raine C, McFarland HF, Hohlfeld R (eds) Multiple Sclerosis: a comprehensive text. Saunders Elsevier, Edinburgh, pp 100–120
5.
Zurück zum Zitat Andersen O (1980) Restricted dissemination of clinically defined attacks in an MS incidence material. Acta Neurol Scand Suppl 77:1–70PubMed Andersen O (1980) Restricted dissemination of clinically defined attacks in an MS incidence material. Acta Neurol Scand Suppl 77:1–70PubMed
6.
Zurück zum Zitat Bostrom I, Callander M, Kurtzke JF, Landtblom AM (2009) High prevalence of multiple sclerosis in the Swedish county of Varmland. Mult Scler 15:1253–1262CrossRefPubMed Bostrom I, Callander M, Kurtzke JF, Landtblom AM (2009) High prevalence of multiple sclerosis in the Swedish county of Varmland. Mult Scler 15:1253–1262CrossRefPubMed
7.
Zurück zum Zitat Broman T, Andersen O, Bergmann L (1981) Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 63:6–33CrossRefPubMed Broman T, Andersen O, Bergmann L (1981) Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 63:6–33CrossRefPubMed
8.
Zurück zum Zitat Bronnum-Hansen H, Koch-Henriksen N, Hyllested K (1994) Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 44:1901–1907CrossRefPubMed Bronnum-Hansen H, Koch-Henriksen N, Hyllested K (1994) Survival of patients with multiple sclerosis in Denmark: a nationwide, long-term epidemiologic survey. Neurology 44:1901–1907CrossRefPubMed
9.
Zurück zum Zitat Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hagglund H, Carlson K, Fagius J (2014) Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 85:1116–1121CrossRefPubMed Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, Vrethem M, Fredrikson S, Martin C, Sandstedt A, Uggla B, Lenhoff S, Johansson JE, Isaksson C, Hagglund H, Carlson K, Fagius J (2014) Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 85:1116–1121CrossRefPubMed
10.
Zurück zum Zitat Christiansen CF, Christensen S, Farkas DK, Miret M, Sorensen HT, Pedersen L (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35:267–274CrossRefPubMed Christiansen CF, Christensen S, Farkas DK, Miret M, Sorensen HT, Pedersen L (2010) Risk of arterial cardiovascular diseases in patients with multiple sclerosis: a population-based cohort study. Neuroepidemiology 35:267–274CrossRefPubMed
11.
Zurück zum Zitat Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129:595–605CrossRefPubMed Confavreux C, Vukusic S (2006) Age at disability milestones in multiple sclerosis. Brain 129:595–605CrossRefPubMed
12.
Zurück zum Zitat Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616CrossRefPubMed Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129:606–616CrossRefPubMed
13.
Zurück zum Zitat Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782CrossRefPubMed Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782CrossRefPubMed
14.
Zurück zum Zitat D’Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J (2011) Vascular aspects of multiple sclerosis. Lancet Neurol 10:657–666CrossRefPubMed D’Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J (2011) Vascular aspects of multiple sclerosis. Lancet Neurol 10:657–666CrossRefPubMed
15.
Zurück zum Zitat Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260–274CrossRefPubMed Eriksson M, Andersen O, Runmarker B (2003) Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 9:260–274CrossRefPubMed
16.
Zurück zum Zitat Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand’maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H (2013) Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 136:3609–3617CrossRefPubMed Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand’maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H (2013) Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain 136:3609–3617CrossRefPubMed
17.
Zurück zum Zitat Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765–772CrossRefPubMed Kantarci O, Siva A, Eraksoy M, Karabudak R, Sutlas N, Agaoglu J, Turan F, Ozmenoglu M, Togrul E, Demirkiran M (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765–772CrossRefPubMed
18.
Zurück zum Zitat Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15:146–158PubMedCentralCrossRefPubMed Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, Herbert J (2013) Natural history of multiple sclerosis symptoms. Int J MS Care 15:146–158PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Kister I, Chamot E, Bacon JH, Cutter G, Herbert J (2011) Trend for decreasing multiple sclerosis severity scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler 17:725–733CrossRefPubMed Kister I, Chamot E, Bacon JH, Cutter G, Herbert J (2011) Trend for decreasing multiple sclerosis severity scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler 17:725–733CrossRefPubMed
20.
Zurück zum Zitat Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand’Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J (2012) Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci 318:94–99CrossRefPubMed Kister I, Chamot E, Cutter G, Bacon TE, Jokubaitis VG, Hughes SE, Gray OM, Trojano M, Izquierdo G, Grand’Maison F, Duquette P, Lugaresi A, Grammond P, Boz C, Hupperts R, Petersen T, Giuliani G, Oreja-Guevara C, Iuliano G, Lechner-Scott J, Bergamaschi R, Rio ME, Verheul F, Fiol M, Van Pesch V, Slee M, Butzkueven H, Herbert J (2012) Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci 318:94–99CrossRefPubMed
21.
Zurück zum Zitat Koch M, Kingwell E, Rieckmann P, Tremlett H (2010) The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1039–1043CrossRefPubMed Koch M, Kingwell E, Rieckmann P, Tremlett H (2010) The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81:1039–1043CrossRefPubMed
22.
Zurück zum Zitat Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129:584–594CrossRefPubMed Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (2006) The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129:584–594CrossRefPubMed
23.
Zurück zum Zitat Kurland LT (1994) The evolution of multiple sclerosis epidemiology. Ann Neurol 36(Suppl):S2–S5CrossRefPubMed Kurland LT (1994) The evolution of multiple sclerosis epidemiology. Ann Neurol 36(Suppl):S2–S5CrossRefPubMed
24.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452CrossRefPubMed
25.
Zurück zum Zitat Levic ZM, Dujmovic I, Pekmezovic T, Jarebinski M, Marinkovic J, Stojsavljevic N, Drulovic J (1999) Prognostic factors for survival in multiple sclerosis. Mult Scler 5:171–178CrossRefPubMed Levic ZM, Dujmovic I, Pekmezovic T, Jarebinski M, Marinkovic J, Stojsavljevic N, Drulovic J (1999) Prognostic factors for survival in multiple sclerosis. Mult Scler 5:171–178CrossRefPubMed
26.
Zurück zum Zitat Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMed Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911CrossRefPubMed
27.
Zurück zum Zitat Magyari M, Koch-Henriksen N, Pfleger CC, Soelberg Sörensen P (2014) Physical and social environment and the risk of multiple sclerosis. Multiple sclerosis and related disorders 3:600–606CrossRefPubMed Magyari M, Koch-Henriksen N, Pfleger CC, Soelberg Sörensen P (2014) Physical and social environment and the risk of multiple sclerosis. Multiple sclerosis and related disorders 3:600–606CrossRefPubMed
28.
Zurück zum Zitat Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T (2005) Changes in the ascertainment of multiple sclerosis. Neurology 65:1066–1070CrossRefPubMed Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T (2005) Changes in the ascertainment of multiple sclerosis. Neurology 65:1066–1070CrossRefPubMed
29.
Zurück zum Zitat Miller DH, Chard DT, Ciccarelli O (2012) Clinically isolated syndromes. Lancet Neurol 11:157–169CrossRefPubMed Miller DH, Chard DT, Ciccarelli O (2012) Clinically isolated syndromes. Lancet Neurol 11:157–169CrossRefPubMed
30.
Zurück zum Zitat Muller R (1951) Course and prognosis of disseminated sclerosis in relation to age of onset. AMA Arch Neurol Psychiatry 66:561–570CrossRefPubMed Muller R (1951) Course and prognosis of disseminated sclerosis in relation to age of onset. AMA Arch Neurol Psychiatry 66:561–570CrossRefPubMed
31.
Zurück zum Zitat Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, Hjalgrim H (2006) Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 118:979–984CrossRefPubMed Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, Hjalgrim H (2006) Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 118:979–984CrossRefPubMed
32.
Zurück zum Zitat Novakova L, Skoog B, Runmarker B, Ekholm S, Winblad S, Lisovskaja V, Andersen O (2013) Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy. Mult Scler J 20:496–500CrossRef Novakova L, Skoog B, Runmarker B, Ekholm S, Winblad S, Lisovskaja V, Andersen O (2013) Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy. Mult Scler J 20:496–500CrossRef
33.
Zurück zum Zitat Roberts RS, Spitzer WO, Delmore T, Sackett DL (1978) An empirical demonstration of Berkson’s bias. J Chronic Dis 31:119–128CrossRefPubMed Roberts RS, Spitzer WO, Delmore T, Sackett DL (1978) An empirical demonstration of Berkson’s bias. J Chronic Dis 31:119–128CrossRefPubMed
34.
Zurück zum Zitat Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250CrossRefPubMed Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT (1995) Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 45:244–250CrossRefPubMed
35.
Zurück zum Zitat Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116(Pt 1):117–134CrossRefPubMed Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116(Pt 1):117–134CrossRefPubMed
36.
Zurück zum Zitat Runmarker B, Andersson C, Oden A, Andersen O (1994) Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 241:597–604CrossRefPubMed Runmarker B, Andersson C, Oden A, Andersen O (1994) Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol 241:597–604CrossRefPubMed
37.
Zurück zum Zitat Runmarker B, Martinsson T, Wahlstrom J, Andersen O (1994) HLA and prognosis in multiple sclerosis. J Neurol 241:385–390CrossRefPubMed Runmarker B, Martinsson T, Wahlstrom J, Andersen O (1994) HLA and prognosis in multiple sclerosis. J Neurol 241:385–390CrossRefPubMed
38.
Zurück zum Zitat Salhofer-Polanyi S, Windt J, Sumper H, Grill H, Essmeister M, Diermayr G, Zebenholzer K, Leutmezer F, Zulehner G, Vass K, Asenbaum-Nan S (2013) Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. Neuro Rehabilitation 33:285–292PubMed Salhofer-Polanyi S, Windt J, Sumper H, Grill H, Essmeister M, Diermayr G, Zebenholzer K, Leutmezer F, Zulehner G, Vass K, Asenbaum-Nan S (2013) Benefits of inpatient multidisciplinary rehabilitation in multiple sclerosis. Neuro Rehabilitation 33:285–292PubMed
39.
Zurück zum Zitat Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC (2014) Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85:67–75CrossRefPubMed Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC (2014) Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85:67–75CrossRefPubMed
40.
Zurück zum Zitat Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929PubMedCentralCrossRefPubMed Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC (2010) The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain 133:1914–1929PubMedCentralCrossRefPubMed
41.
Zurück zum Zitat Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O (2012) A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain 135:900–911CrossRefPubMed Skoog B, Runmarker B, Winblad S, Ekholm S, Andersen O (2012) A representative cohort of patients with non-progressive multiple sclerosis at the age of normal life expectancy. Brain 135:900–911CrossRefPubMed
42.
Zurück zum Zitat Skoog B, Tedeholm H, Runmarker B, Odén A, Andersen O (2014) Continuous prediction of secondary progression in the individual course of multiple scleosis. Mult Scler Relat Dis 3:584–592CrossRef Skoog B, Tedeholm H, Runmarker B, Odén A, Andersen O (2014) Continuous prediction of secondary progression in the individual course of multiple scleosis. Mult Scler Relat Dis 3:584–592CrossRef
43.
Zurück zum Zitat Svenningsson A, Runmarker B, Lycke J, Andersen O (1990) Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand 82:161–168CrossRefPubMed Svenningsson A, Runmarker B, Lycke J, Andersen O (1990) Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. Acta Neurol Scand 82:161–168CrossRefPubMed
44.
Zurück zum Zitat Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmestrom C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O (2013) Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 19:765–774PubMedCentralCrossRefPubMed Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmestrom C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O (2013) Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler 19:765–774PubMedCentralCrossRefPubMed
45.
Zurück zum Zitat Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172–177CrossRefPubMed Tremlett H, Paty D, Devonshire V (2006) Disability progression in multiple sclerosis is slower than previously reported. Neurology 66:172–177CrossRefPubMed
46.
Zurück zum Zitat Tremlett H, Yinshan Z, Devonshire V (2008) Natural history of secondary-progressive multiple sclerosis. Mult Scler 14:314–324CrossRefPubMed Tremlett H, Yinshan Z, Devonshire V (2008) Natural history of secondary-progressive multiple sclerosis. Mult Scler 14:314–324CrossRefPubMed
47.
Zurück zum Zitat Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73:1616–1623PubMedCentralCrossRefPubMed Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y (2009) Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 73:1616–1623PubMedCentralCrossRefPubMed
48.
Zurück zum Zitat Tremlett H, Zhao Y, Devonshire V (2009) Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 256:374–381CrossRefPubMed Tremlett H, Zhao Y, Devonshire V (2009) Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol 256:374–381CrossRefPubMed
49.
Zurück zum Zitat Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Jones J, Compston DA, Coles A (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 86:208–215CrossRefPubMed Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Jones J, Compston DA, Coles A (2015) Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 86:208–215CrossRefPubMed
50.
Zurück zum Zitat Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19:188–198PubMedCentralCrossRefPubMed Tutuncu M, Tang J, Zeid NA, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH (2013) Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 19:188–198PubMedCentralCrossRefPubMed
51.
Zurück zum Zitat Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(Pt 6):1419–1428 Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112(Pt 6):1419–1428
52.
Zurück zum Zitat Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. clinical course and disability. Brain 112(Pt 1):133–146CrossRefPubMed Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. clinical course and disability. Brain 112(Pt 1):133–146CrossRefPubMed
53.
Zurück zum Zitat Vukusic S, Confavreux C (2003) Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206:135–137CrossRefPubMed Vukusic S, Confavreux C (2003) Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 206:135–137CrossRefPubMed
54.
Zurück zum Zitat Yamout B, Itani S, Arabi A, Hamzeh D, Yaghi S (2010) Prognostic factors of multiple sclerosis in Lebanon. Int J Neurosci 120:206–210CrossRefPubMed Yamout B, Itani S, Arabi A, Hamzeh D, Yaghi S (2010) Prognostic factors of multiple sclerosis in Lebanon. Int J Neurosci 120:206–210CrossRefPubMed
Metadaten
Titel
The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset
verfasst von
Helen Tedeholm
Bengt Skoog
Vera Lisovskaja
Björn Runmarker
Olle Nerman
Oluf Andersen
Publikationsdatum
01.05.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 5/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7674-y

Weitere Artikel der Ausgabe 5/2015

Journal of Neurology 5/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.